-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor Today, Neuron23 announced the completion of a $100 million Series C financing
.
The funds obtained from this round of financing will be used to promote the company's flagship R&D projects targeting LRRK2 and TYK2
.
LRRK2 is a gene associated with Parkinson's disease and systemic inflammatory diseases
.
TYK2 is a member of the JAK protein family and plays an important role in pathological immune signaling
.
LRRK2 is a multi-protein domain complex protein found in neurons and other tissues and cell types throughout the body
.
Variations in the LRRK2 gene are the most common genetic mutations in hereditary Parkinson's disease
.
Emerging evidence suggests that LRRK2 activity also plays a role in certain subsets of patients with non-familial Parkinson's disease
.
Neuron23's pipeline includes multiple LRRK2-targeting compounds
.
The company said it has identified a potential "best-in-class" blood-brain barrier-crossing LRRK2 inhibitor called NEU-723 as a clinical candidate for Parkinson's disease
.
Clinical trials of NEU-723 are expected to be initiated before the end of 2022
.
Founded in 2018, Neuron23 is committed to harnessing the latest advances in human genetics, combined with cutting-edge AI-powered drug discovery and biomarker platforms, to develop innovative treatments for serious diseases
.
The company focuses on neurodegenerative, neuroinflammatory, systemic autoimmune and inflammatory diseases
.
"This funding round represents strong support for Neuron23's precision neurology R&D strategy
.
"Taking our LRRK2 Parkinson's disease program as an example, we aim to use cutting-edge machine learning tools to identify patients most likely to benefit from our therapies and improve the success of clinical development," said Dr.
Nancy Stagliano, CEO of Neuron23.
rate and bring the right medicine to the right patient
.
Now is a good time to revolutionize drug development for neurodegenerative diseases
.
"Reference: [1] Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease.
Retrieved March 30, 2022, from https:// million-series-c-financing-round-nominates-clinical-candidate-for-parkinsons-disease-301513270.
htmlDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only.
The opinions expressed in this article do not represent the position of WuXi AppTec, nor do they support or oppose the opinions expressed in the article
.
This article is not a recommendation for treatment plans
.
For guidance on treatment plans, please go to a regular hospital for treatment
.
.
The funds obtained from this round of financing will be used to promote the company's flagship R&D projects targeting LRRK2 and TYK2
.
LRRK2 is a gene associated with Parkinson's disease and systemic inflammatory diseases
.
TYK2 is a member of the JAK protein family and plays an important role in pathological immune signaling
.
LRRK2 is a multi-protein domain complex protein found in neurons and other tissues and cell types throughout the body
.
Variations in the LRRK2 gene are the most common genetic mutations in hereditary Parkinson's disease
.
Emerging evidence suggests that LRRK2 activity also plays a role in certain subsets of patients with non-familial Parkinson's disease
.
Neuron23's pipeline includes multiple LRRK2-targeting compounds
.
The company said it has identified a potential "best-in-class" blood-brain barrier-crossing LRRK2 inhibitor called NEU-723 as a clinical candidate for Parkinson's disease
.
Clinical trials of NEU-723 are expected to be initiated before the end of 2022
.
Founded in 2018, Neuron23 is committed to harnessing the latest advances in human genetics, combined with cutting-edge AI-powered drug discovery and biomarker platforms, to develop innovative treatments for serious diseases
.
The company focuses on neurodegenerative, neuroinflammatory, systemic autoimmune and inflammatory diseases
.
"This funding round represents strong support for Neuron23's precision neurology R&D strategy
.
"Taking our LRRK2 Parkinson's disease program as an example, we aim to use cutting-edge machine learning tools to identify patients most likely to benefit from our therapies and improve the success of clinical development," said Dr.
Nancy Stagliano, CEO of Neuron23.
rate and bring the right medicine to the right patient
.
Now is a good time to revolutionize drug development for neurodegenerative diseases
.
"Reference: [1] Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease.
Retrieved March 30, 2022, from https:// million-series-c-financing-round-nominates-clinical-candidate-for-parkinsons-disease-301513270.
htmlDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only.
The opinions expressed in this article do not represent the position of WuXi AppTec, nor do they support or oppose the opinions expressed in the article
.
This article is not a recommendation for treatment plans
.
For guidance on treatment plans, please go to a regular hospital for treatment
.
